Literature DB >> 3598056

[Efficacy of specific chemotherapy in the prevention of recurrences of toxoplasmic chorioretinitis during the 4 years following the treatment].

J C Timsit, E Bloch-Michel.   

Abstract

The effectiveness of a curative or preventive therapy in toxoplasmic retinochoroiditis is difficult to evaluate clinically. The goal of the present paper was to study the recurrence rate of ocular toxoplasmosis during a four years period following a Pyrimethamine-sulfadiazine therapy. Some case had received previous therapy (systemic steroids alone or in combination with Spiramycin) which had not effected a lasting cure. In this series of 54 patients diagnosed as having active toxoplasmosis chorioretinitis, the combination of Pyrimethamine and Sulfadiazine seems statistically more effective than other reported treatments. The recurrence rate in a four years follow up study was 40 percent. The benefit of the therapy is more obvious in severe toxoplasmosis uveitis (with severe vitreous reaction, high recurrence rate, macular lesions). The treatment was less effective when indicated after an ineffective previous therapy. The dosage and the duration of the therapy must be adapted to each case. No complication was experienced during the treatment. In order to prevent recurrent toxoplasmosis uveitis Pyrimethamine-Sulfadiazine therapy appears to be the only effective synergistic therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598056

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  6 in total

Review 1.  Ocular toxoplasmosis--clinical aspect.

Authors:  E Bloch-Michel
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

2.  Clinical manifestation and prognosis of active ocular toxoplasmosis in Iran.

Authors:  Farzan Kianersi; Afsaneh Naderi Beni; Zahra Naderi Beni
Journal:  Int Ophthalmol       Date:  2012-06-26       Impact factor: 2.031

3.  Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention.

Authors:  Norman A Saffra; Carly J Seidman; Louis M Weiss
Journal:  J Neuroinfect Dis       Date:  2013

Review 4.  Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Authors:  Smitha Jasper; Satyanarayana S Vedula; Sheeja S John; Saban Horo; Yasir J Sepah; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2017-01-26

Review 5.  Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Authors:  Smitha Jasper; Satyanarayana S Vedula; Sheeja S John; Saban Horo; Yasir J Sepah; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

Review 6.  Management of toxoplasmosis.

Authors:  V S Georgiev
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.